You are here

Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.

TitleAmyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
Publication TypeJournal Article
Year of Publication2021
AuthorsDeters KD, Napolioni V, Sperling RA, Greicius MD, Mayeux R, Hohman T, Mormino EC
JournalNeurology
Volume96
Issue11
Paginatione1491-e1500
Date Published2021 03 16
ISSN1526-632X
KeywordsAfrican Americans, Aged, Aged, 80 and over, Alzheimer Disease, Amyloidogenic Proteins, Apolipoproteins E, Biomarkers, Brain, Female, Humans, Male, Positron-Emission Tomography, United States
Abstract

OBJECTIVE: To examine whether amyloid PET in cognitively normal (CN) individuals screened for the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) study differed across self-identified non-Hispanic White and Black (NHW and NHB) groups.
METHODS: We examined 3,689 NHW and 144 NHB participants who passed initial screening for the A4 study and underwent amyloid PET. The effect of race on amyloid PET was examined using logistic (dichotomous groups) and linear (continuous values) regression controlling for age, sex, and number of ε4 and ε2 alleles. Associations between amyloid and genetically determined ancestry (reflecting African, South Asian, East Asian, American, and European populations) were tested within the NHB group. Potential interactions with were assessed.
RESULTS: NHB participants had lower rates of amyloid positivity and lower continuous amyloid levels compared to NHW participants. This race effect on amyloid was strongest in the ε4 group. Within NHB participants, those with a lower percentage of African ancestry had higher amyloid. A greater proportion of NHB participants did not pass initial screening compared to NHW participants, suggesting potential sources of bias related to race in the A4 PET data.
CONCLUSION: Reduced amyloid was observed in self-identified NHB participants who passed initial eligibility criteria for the A4 study. This work stresses the importance of investigating AD biomarkers in ancestrally diverse samples as well as the need for careful consideration regarding study eligibility criteria in AD prevention trials.

DOI10.1212/WNL.0000000000011599
Pubmed Linkhttps://www.ncbi.nlm.nih.gov/pubmed/33568538?dopt=Abstract
page_expoExternal
Alternate JournalNeurology
PubMed ID33568538
PubMed Central IDPMC8032379
Grant ListR01 AG063689 / AG / NIA NIH HHS / United States
P30 AG059307 / AG / NIA NIH HHS / United States
P30 AG066515 / AG / NIA NIH HHS / United States
R01 AG059716 / AG / NIA NIH HHS / United States
K01 AG049164 / AG / NIA NIH HHS / United States
K01 AG051718 / AG / NIA NIH HHS / United States

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer